文献速递心力衰竭与心肌病

同种异体与自体间充质干细胞治疗非缺血性扩张型心肌病的随机对照研究:POSEIDON-DCM试验

Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy: POSEIDON-DCM Trial.
PubMed 文献 · J Am Coll Cardiol · 2016-11-14

POSEIDON-DCM试验将37例非缺血性扩张型心肌病患者按1:1随机分配接受同种异体或自体骨髓来源间充质干细胞(1亿个)经心内膜注射。12个月时同种异体组严重不良事件发生率28.2% vs 自体组63.5%(p=0.1004),射血分数提升8.0个百分点(p=0.004 vs 基线),6分钟步行距离增加37.0米(p=0.04),主要不良心脏事件率更低(p=0.0186)。结论提示同种异体间充质干细胞安全且有效。

要点

  • 同种异体间充质干细胞12个月严重不良事件率28.2%,低于自体组的63.5%。
  • 同种异体组射血分数提升8.0个百分点(p=0.004 vs 基线)。
  • 同种异体组6分钟步行距离增加37.0米(p=0.04),主要不良心脏事件率更低(p=0.0186)。

核心结论

  • 同种异体间充质干细胞在非缺血性扩张型心肌病中显示出安全性和有临床意义的疗效,优于自体间充质干细胞。

研究设计与样本

  • 随机对照试验,37例慢性非缺血性扩张型心肌病患者按1:1随机接受同种异体或自体骨髓来源间充质干细胞(1亿个)经心内膜注射。
  • 患者于2011年12月至2015年7月在迈阿密大学医院招募,随访至12个月评估安全性和有效性终点。

主要发现

  • 30天内无治疗相关严重不良事件;12个月严重不良事件发生率同种异体组28.2% vs 自体组63.5%(p=0.1004)。
  • 同种异体组射血分数提升8.0个百分点(p=0.004 vs 基线),自体组提升5.4个百分点(p=0.116 vs 基线;组间p=0.4887)。
  • 同种异体组6分钟步行距离增加37.0米(p=0.04),自体组增加7.3米(p=0.71;组间p=0.0168)。
  • 同种异体组主要不良心脏事件率更低(p=0.0186 vs 自体组);肿瘤坏死因子-α两组均下降(各p=0.0001),6个月时同种异体组下降更显著(p=0.05)。
  • 1例同种异体组患者出现供者特异性计算群体反应性抗体水平升高(>80)。

关键数值与推荐

  • 同种异体组12个月严重不良事件发生率28.2%,自体组63.5%(p=0.1004)。
  • 同种异体组射血分数提升8.0个百分点(p=0.004),自体组提升5.4个百分点(p=0.116;组间p=0.4887)。
  • 同种异体组6分钟步行距离增加37.0米(p=0.04),自体组增加7.3米(p=0.71;组间p=0.0168)。
  • 同种异体组主要不良心脏事件率低于自体组(p=0.0186)。
  • 同种异体组肿瘤坏死因子-α下降更显著(6个月时组间p=0.05)。

临床怎么用

  • 同种异体间充质干细胞经心内膜注射可能作为非缺血性扩张型心肌病的治疗选择,需进一步 pivotal 试验验证。

局限性

  • 样本量小(37例),严重不良事件比较未达统计学显著性(p=0.1004)。
  • 单中心研究,随访12个月,长期安全性和有效性未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although human mesenchymal stem cells (hMSCs) have been tested in ischemic cardiomyopathy, few studies exist in chronic nonischemic dilated cardiomyopathy (NIDCM). OBJECTIVES: The authors conducted a randomized comparison of safety and efficacy of autologous (auto) versus allogeneic (allo) bone marrow-derived hMSCs in NIDCM. METHODS: Thirty-seven patients were randomized to either allo- or auto-hMSCs in a 1:1 ratio. Patients were recruited between December 2011 and July 2015 at the University of Miami Hospital. Patients received hMSCs (100 million) by transendocardial stem cell injection in 10 left ventricular sites. Treated patients were evaluated at baseline, 30 days, and 3-, 6-, and 12-months for safety (serious adverse events [SAE]), and efficacy endpoints: ejection fraction, Minnesota Living with Heart Failure Questionnaire, 6-min walk test, major adverse cardiac events, and immune biomarkers. RESULTS: There were no 30-day treatment-emergent SAEs. Twelve-month SAE incidence was 28.2% with allo-hMSCs versus 63.5% with auto-hMSCs (p = 0.1004 for the comparison). One allo-hMSC patient developed an elevated (>80) donor-specific calculated panel reactive antibody level. The ejection fraction increased in allo-hMSC patients by 8.0 percentage points (p = 0.004) compared with 5.4 with auto-hMSCs (p = 0.116; allo vs. auto p = 0.4887). The 6-min walk test increased with allo-hMSCs by 37.0 m (p = 0.04), but not auto-hMSCs at 7.3 m (p = 0.71; auto vs. allo p = 0.0168). MLHFQ score decreased in allo-hMSC (p = 0.0022) and auto-hMSC patients (p = 0.463; auto vs. allo p = 0.172). The major adverse cardiac event rate was lower, too, in the allo group (p = 0.0186 vs. auto). Tumor necrosis factor-α decreased (p = 0.0001 for each), to a greater extent with allo-hMSCs versus auto-hMSCs at 6 months (p = 0.05). CONCLUSIONS: These findings demonstrated safety and clinically meaningful efficacy of allo-hMSC versus auto-hMSC in NIDCM patients. Pivotal trials of allo-hMSCs are warranted based on these results. (Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy [PoseidonDCM]; NCT01392625).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Hare JM, DiFede DL, Rieger AC, et al. Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy: POSEIDON-DCM Trial. J Am Coll Cardiol. 2016. PMID: 27856208. doi:10.1016/j.jacc.2016.11.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。